Top

Published in:

01-12-2016 | Epidemiology

Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study

Authors: Marian L. Neuhouser, Ashley Wilder Smith, Stephanie M. George, James T. Gibson, Kathy B. Baumgartner, Richard Baumgartner, Catherine Duggan, Leslie Bernstein, Anne McTiernan, Rachel Ballard

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

Purpose

Use of complementary and alternative medicine (CAM) is common among breast cancer patients, but less is known about whether CAM influences breast cancer survival.

Methods

Health Eating, Activity, and Lifestyle (HEAL) Study participants (n = 707) were diagnosed with stage I–IIIA breast cancer. Participants completed a 30-month post-diagnosis interview including questions on CAM use (natural products such as dietary and botanical supplements, alternative health practices, and alternative medical systems), weight, physical activity, and comorbidities. Outcomes were breast cancer-specific and total mortality, which were ascertained from the Surveillance Epidemiology and End Results registries in Western Washington, Los Angeles County, and New Mexico. Cox proportional hazards regression models were fit to data to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for mortality. Models were adjusted for potential confounding by sociodemographic, health, and cancer-related factors.

Results

Among 707 participants, 70 breast cancer-specific deaths and 149 total deaths were reported. 60.2 % of participants reported CAM use post-diagnosis. The most common CAM were natural products (51 %) including plant-based estrogenic supplements (42 %). Manipulative and body-based practices and alternative medical systems were used by 27 and 13 % of participants, respectively. No associations were observed between CAM use and breast cancer-specific (HR 1.04, 95 % CI 0.61–1.76) or total mortality (HR 0.91, 95 % CI 0.63–1.29).

Conclusion

Complementary and alternative medicine use was not associated with breast cancer-specific mortality or total mortality. Randomized controlled trials may be needed to definitively test whether there is harm or benefit from the types of CAM assessed in HEAL in relation to mortality outcomes in breast cancer survivors.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMed

Demark-Wahnefried W, Clipp EC, Lipkus IM et al (2007) Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 25(19):2709–2718CrossRefPubMed

Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103(3):323–328PubMed

Adams RN, Mosher CE, Blair CK, Snyder DC, Sloane R, Demark-Wahnefried W (2015) Cancer survivors’ uptake and adherence in diet and exercise intervention trials: an integrative data analysis. Cancer 121(1):77–83CrossRefPubMed

Demark-Wahnefried W, Rogers LQ, Alfano CM et al (2015) Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin 65(3):167–189CrossRefPubMed

Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340(22):1733–1739CrossRefPubMed

Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280(18):1569–1575CrossRefPubMed

Mao JJ, Palmer SC, Straton JB et al (2008) Cancer survivors with unmet needs were more likely to use complementary and alternative medicine. J Cancer Surviv 2(2):116–124CrossRefPubMed

Matthews AK, Sellergren SA, Huo D, List M, Fleming G (2007) Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13(5):555–562CrossRefPubMed

10.

Wanchai A, Armer JM, Stewart BR (2010) Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs 14(4):E45–E55CrossRefPubMed

11.

Hedderson MM, Patterson RE, Neuhouser ML et al (2004) Sex differences in motives for use of complementary and alternative medicine among cancer patients. Altern Ther Health Med 10(5):58–64PubMed

12.

Patterson RE, Neuhouser ML, Hedderson MM et al (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8(4):477–485CrossRefPubMed

13.

McLay JS, Stewart D, George J, Rore C, Heys SD (2012) Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol 68(5):811–819CrossRefPubMed

14.

Pedersen CG, Christensen S, Jensen AB, Zachariae R (2009) Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45(18):3172–3181CrossRefPubMed

15.

Rebbeck TR, Troxel AB, Norman S et al (2007) A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 120(7):1523–1528CrossRefPubMed

16.

Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J (2006) Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 145(12):869–879CrossRefPubMed

17.

McTiernan A, Rajan KB, Tworoger SS et al (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961–1966CrossRefPubMedPubMedCentral

18.

Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953–958CrossRefPubMed

19.

Wayne SJ, Neuhouser ML, Koprowski C et al (2009) Breast cancer survivors who use estrogenic botanical supplements have lower serum estrogen levels than non users. Breast Cancer Res Treat 117(1):111–119CrossRefPubMed

20.

Ma H, Sullivan-Halley J, Smith AW et al (2011) Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report. BMC Complement Altern Med 11:109CrossRefPubMedPubMedCentral

21.

Gruendwald J, Brendler T, Jaenicke C (2007) Physician’s desk reference for herbal products, 4th edn. Thompson Healthcare, Montvale

22.

Cassileth BRLC (2003) Herb-drug interactions in oncology. BC Decker I, New York

23.

Natural medicine comprehensive database (2007). www.naturaldatabase.com Accessed 11 Jun 2006

24.

Harlan LC, Klabunde CN, Ambs AH et al (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3(2):89–98CrossRefPubMedPubMedCentral

25.

Villasenor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J Cancer Surviv 6(4):398–406CrossRefPubMedPubMedCentral

26.

George SM, Irwin ML, Smith AW et al (2011) Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer. Cancer Causes Control 22(4):589–598CrossRefPubMedPubMedCentral

27.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

28.

Greenlee H, Kwan ML, Ergas IJ et al (2014) Changes in vitamin and mineral supplement use after breast cancer diagnosis in the pathways study: a prospective cohort study. BMC Cancer 14:382CrossRefPubMedPubMedCentral

29.

John GM, Hershman DL, Falci L, Shi Z, Tsai WY, Greenlee H (2016) Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv. doi:10.1007/s11764-016-0530-y PubMed

30.

Greenlee H, Kwan ML, Ergas IJ et al (2009) Complementary and alternative therapy use before and after breast cancer diagnosis: the pathways study. Breast Cancer Res Treat 117(3):653–665CrossRefPubMedPubMedCentral

31.

Wyatt G, Sikorskii A, Rahbar MH, Victorson D, Adams L (2010) Intervention fidelity: aspects of complementary and alternative medicine research. Cancer Nurs 33(5):331–342CrossRefPubMedPubMedCentral

32.

Roberts H (2010) Safety of herbal medicinal products in women with breast cancer. Maturitas 66(4):363–369CrossRefPubMed

33.

Greenlee H, Balneaves LG, Carlson LE et al (2014) Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr 2014(50):346–358CrossRefPubMedPubMedCentral

34.

Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741CrossRefPubMed

35.

Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269CrossRefPubMedPubMedCentral

36.

Chirgwin JH, Giobbie-Hurder A, Coates AS et al (2016) Treatment adherence and its impact on disease-free survival in the breast international group 1–98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. doi:10.1200/JCO.2015.63.8619

37.

Dai Q, Franke AA, Yu H et al (2003) Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiol Biomark Prev 12(6):497–502

38.

Allred CD, Ju YH, Allred KF, Chang J, Helferich WG (2001) Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 22(10):1667–1673CrossRefPubMed

39.

Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474–2477PubMed

40.

Greenlee H, Neugut AI, Falci L et al (2016) Association between complementary and alternative medicine use and breast cancer chemotherapy initiation: the Breast Cancer Quality of Care (BQUAL) study. JAMA Oncol 2(9):1170–1176CrossRefPubMed

41.

Ma H, Carpenter CL, Sullivan-Halley J, Bernstein L (2011) The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors-results of a prospective study. BMC Cancer 11:222CrossRefPubMedPubMedCentral

42.

Caan BJ, Natarajan L, Parker B et al (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomark Prev 20(5):854–858CrossRef

43.

Shu XO, Zheng Y, Cai H et al (2009) Soy food intake and breast cancer survival. JAMA 302(22):2437–2443CrossRefPubMedPubMedCentral

44.

Bright-Gbebry M, Makambi KH, Rohan JP et al (2011) Use of multivitamins, folic acid and herbal supplements among breast cancer survivors: the black women’s health study. BMC Complement Altern Med 11:30CrossRefPubMedPubMedCentral

45.

Greenlee H, Kwan ML, Kushi LH et al (2012) Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer 118(8):2048–2058CrossRefPubMed

46.

Nechuta S, Lu W, Chen Z et al (2011) Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomark Prev 20(2):262–271CrossRef

47.

Hietala M, Henningson M, Ingvar C, Jonsson PE, Rose C, Jernstrom H (2011) Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. Acta Oncol 50(1):134–143CrossRefPubMed

48.

Han E, Johnson N, DelaMelena T, Glissmeyer M, Steinbock K (2011) Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol 18(4):912–916CrossRefPubMed

49.

Hathcock J (2001) Dietary supplements: how they are used and regulated. J Nutr 131(3s):1114S–1117SPubMed

Title: Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study
Authors: Marian L. Neuhouser
Ashley Wilder Smith
Stephanie M. George
James T. Gibson
Kathy B. Baumgartner
Richard Baumgartner
Catherine Duggan
Leslie Bernstein
Anne McTiernan
Rachel Ballard
Publication date: 01-12-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-4010-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials

Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk

Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

Investigation of breast cancer sub-populations in black and white women in South Africa

Keynote webinar | Spotlight on antibody–drug conjugates in cancer